Skip to content
MarketScale
‹ Back to IndustriesSciences

NASA Scrubs First Test Flight of Moon Rocket After Engine Fault

(Bloomberg) — NASA is delaying the debut launch of its new massive rocket due to an issue with one of the rocket’s main engines in another setback for its plan to orbit the moon and return to Earth. The Space Launch System, or SLS, rocket launch which was expected early Monday will be rescheduled, the…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
NASA Scrubs First Test Flight of Moon Rocket After Engine Fault

Key takeaways

01

(Bloomberg) — NASA is delaying the debut launch of its new massive rocket due to an issue with one of the rocket’s main engines in another setback for its plan to orbit the moon and return to Earth.

02

The Space Launch System, or SLS, rocket launch which was expected early Monday will be rescheduled, the…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

(Bloomberg) — NASA is delaying the debut launch of its new massive rocket due to an issue with one of the rocket’s main engines in another setback for its plan to orbit the moon and return to Earth.

The Space Launch System, or SLS, rocket launch which was expected early Monday will be rescheduled, the space agency said. It could be pushed several days or even multiple weeks.

Official confirmation of the delay came after the space agency spent the early morning hours investigating issues including a potential crack in the material in the main body of the rocket as well as a possible temperature issue with one of the main engines, officials said early Monday. Those came after engineers examined and resolved a suspected leak affecting the hydrogen tanking process.

The uncrewed mission, called Artemis I, will be the first major flight in NASA’s ambitious plan to send the first woman and the first person of color to the lunar surface as early as 2025. Artemis I is aimed at testing out the SLS, made by Boeing Co., and a new deep-space crew capsule called Orion that was developed by Lockheed Martin Corp.

When Artemis I does launch, SLS will be sending Orion on a 42-day mission, along with a host of payloads and sensors to track the journey. The capsule is tasked with inserting itself into lunar orbit and entering deep space before returning to Earth in the Pacific Ocean off San Diego.

The Space Launch System already is more than five years behind schedule. It has been in development for roughly a decade, slowed by a myriad of delays and cost overruns. Development costs of the program have soared from an original $7 billion to about $23 billion, according to an estimate by the Planetary Society.

If successful, the Artemis program — named for the twin sister of the god Apollo in Greek mythology — will see the return of people to the lunar surface for the first time in 50 years. No one has visited the moon since Apollo 17 in December 1972.

More stories like this are available on bloomberg.com.

©2022 Bloomberg L.P.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512